Table 1. Baseline characteristics of patients.
| Feature | Overall (n=296) | Non-csPCa (n=242) (BPH and Gleason <7) | csPCa (n=54) (Gleason ≥7) | P |
|---|---|---|---|---|
| Age (years), mean ± SD | 67.5±7.9 | 66.8±7.8 | 70.4±8.0 | 0.030* |
| Prostate volume (mL), median (IQR) | 44.76 (35.84–57.20) | 44.96 (35.96–59.00) | 43.92 (32.76–51.98) | 0.357 |
| tPSA (ng/mL), median (IQR) | 7.94 (5.90–11.88) | 7.67 (5.63–10.27) | 11.00 (7.21–18.72) | 0.001* |
| %fPSA (%), median (IQR) | 16.89 (12.03–22.25) | 18.21 (12.18–22.87) | 13.66 (11.78–17.56) | 0.099 |
| p2PSA (ng/L), median (IQR) | 15.70 (10.03–25.85) | 13.74 (9.02–22.05) | 30.21 (17.53–95.66) | <0.001* |
| PHI, median (IQR) | 32.52 (23.81–52.75) | 29.41 (21.30–42.78) | 64.14 (40.52–136.23) | <0.001* |
| PHID, median (IQR) | 0.65 (0.51–1.06) | 0.59 (0.47–0.83) | 1.62 (1.02–3.04) | <0.001* |
*, P<0.05 was significant. csPCa, clinically significant prostate cancer; BPH, benign prostatic hyperplasia; IQR, interquartile range; tPSA, total prostate-specific antigen; %fPSA, percentage free prostate-specific antigen; p2PSA, isoform [-2]proPSA; PHI, prostate health index; PHID, prostate health index density; SD, standard deviation.